Cytosorbents (CTSO) Cash from Operations (2010 - 2026)

Cytosorbents has reported Cash from Operations for 17 years, with the latest figure at 1162000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 66.47% year-over-year to 1162000.0; the trailing twelve-month figure through Mar 2026 stood at 10073000.0 (up 22.9% YoY), and the FY2025 full-year result was 12377000.0, up 14.22% from the prior year.
• Cash from Operations for Q1 2026 stood at 1162000.0, up from 4825000.0 in the prior quarter.
• The five-year high for Cash from Operations was 1162000.0 in Q1 2026, with the low at 8119170.0 in Q1 2022.
• Historically, Cash from Operations has averaged 4579789.29 across 5 years, with a median of 4825000.0 in 2025.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 294.84% — and 2025, when it surged 68.52%.
• Cytosorbents' Cash from Operations stood at 5340327.0 in 2022, then retreated by 19.98% to 6407411.0 in 2023, then soared by 63.46% to 2341000.0 in 2024, then plunged by 106.11% to 4825000.0 in 2025, then surged by 75.92% to 1162000.0 in 2026.
• The last three Cash from Operations figures came in at 1162000.0 (Q1 2026), 4825000.0 (Q4 2025), and 2577000.0 (Q3 2025), per Business Quant data.